Metformin 500 mg + Glimepiride 2 mg Tablets
Brand Name: YASGLIF-M2
Metformin 500 mg + Glimepiride 2 mg Tablets
Product Overview
- YASGLIF-M2 is an escalated-dose antidiabetic formulation containing Metformin Hydrochloride 500 mg (PR) and Glimepiride 2 mg. The higher concentration of glimepiride provides enhanced binding to pancreatic SUR1 complexes, driving greater endogenous insulin secretion. Coupled with prolonged-release Metformin’s continuous suppression of hepatic gluconeogenesis and improvement in insulin receptor sensitivity, it effectively manages elevated fasting and post-prandial glycemic levels.
- Designed for individuals requiring stronger blood sugar management, this higher-strength dual pill encourages the pancreas to release additional insulin to process meals while keeping liver sugar production low day and night.
- Developed under stringent quality standards, YASGLIF-M2 ensures consistent efficacy, safety, and patient compliance — empowering physicians to achieve optimal therapeutic outcomes in Progressive Type 2 Diabetes Mellitus.
Therapeutic Benefits / Key Features
- Provides dual mechanism of action for superior glycemic control.
- Enhances insulin sensitivity and pancreatic function simultaneously.
- Sustained-release formulation improves patient adherence and convenience.
- Backed by clinically proven efficacy and metabolic safety profile.
Brand Composition
Each film-coated tablet contains:
- Metformin Hydrochloride I.P. 500 mg
- Glimepiride I.P. 2 mg
Why this formulation matters
- Combines the most trusted first-line and second-line agents in diabetes management.
- Reduces both fasting and postprandial glucose levels effectively.
- Minimizes risk of hypoglycemia compared to monotherapy.
- Proven to improve glycemic parameters and delay disease progression.
Division Identity
Part of Yaselle Diaxen – Diabetes & Endocrine Care Division
Committed to advancing endocrine health through evidence-based innovation.